Biologic Therapy for Osteoarthritis in Minneapolis, MN

Minneapolis epidemiology first — then the SKU

CDC PLACES (2023, crude) estimates 7.4% of adults in Minneapolis have diagnosed diabetes — 4.6 points below the U.S. 12% figure. Obesity 28.6%; arthritis 15.2%. Those three PLACES crude rates (plus Census 429,954) are the local facts on this page. Everything else is the national osteoarthritis biologic therapy catalog and J6 paperwork.

The chart problems we still see in MN

• Adult arthritis here is 15.2% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 9.9% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in Minnesota.
• Chronic wounds that stall past 30 days are the typical entry point for cellular/tissue products. CDC diabetes prevalence is the epidemiologic backdrop; J6 coverage rules are the billing backdrop. Both have to be true on the same chart.
• Minnesota is outside CDC's historical Diabetes Belt core, but the national 12% diabetes figure still applies as a planning baseline until a clinic uses its own payer mix. Clinics asking for regenerative inventory still have to separate HCT/P 361 homologous-use products from unapproved “stem cell” claims (FDA 21 CFR 1271).

City rate, state belt, federal LCD — keep the grains

Three grains, kept separate on purpose. City: Census 429,954 and CDC PLACES crude rates. State: Minnesota Department of Health, Diabetes Belt not in the core list. Federal: 21 CFR 1271 and National Government Services (NGS) LCDs. CDC PLACES (2023, crude) estimates 7.4% of adults in Minneapolis have diagnosed diabetes — 4.6 points below the U.S. 12% figure.

What “ready” looks like in this MAC